Your browser doesn't support javascript.
loading
Treatment of acute and chronic graft-versus-host disease with extracorporeal photopheresis: Update of best practice recommendations from Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO).
Colpo, Anna; Marchetti, Monia; Bianco, Irene; Cruciani, Fabio; Ipsevich, Francesco; Montanari, Mauro; Stanghellini, Maria Teresa Lupo.
Affiliation
  • Colpo A; Therapeutic Apheresis Unit, Department of Transfusion Medicine, Padova University Hospital, Padova, Italy. Electronic address: anna.colpo@aopd.veneto.it.
  • Marchetti M; Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Bianco I; Therapeutic Apheresis Unit, Transfusion Medicine and Transplant Biology, Pisa University Hospital, Pisa, Italy.
  • Cruciani F; Transfusion Medicine Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Ipsevich F; Transfusion Medicine Department, Leukapheresis and Cellular Therapy Unit, S. Camillo-Forlanini Hospital, Rome, Italy.
  • Montanari M; Transfusion Medicine Department, Marche University Hospital, Ancona, Italy.
  • Stanghellini MTL; Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, IRCCS, Milano, Italy.
Transfus Apher Sci ; 63(5): 103990, 2024 Aug 13.
Article in En | MEDLINE | ID: mdl-39208662
ABSTRACT
These guidelines represent a GRADE-method revision of the recommendations produced by the Italian Society of Hemapheresis and Cell Manipulation (SIDEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO) in 2013. Since 2013 several studies have been published that have strengthened the role of ECP in the management of GVHD. Thus, it was deemed appropriate to proceed with an update, with the aim to define uniform criteria for the application of ECP in adult and pediatric patients affected by GVHD throughout the national territory, in line with international guidelines, in maintaining of high standards of safety for patients and quality of the procedures provide. Post-HSCT GvHD therapies other than ECP and ECP therapy of other diseases, such as CTCL, are not covered by these guidelines.The development panel for this guideline includes professionals from various specialties who routinely interact in the management of the patient with GVHD, namely the transfusionist, the adult and pediatric hematologist, and the hospital pharmacist. A hematologist experienced in systematic reviews and GRADE guideline development ccordinated the development process, and an experienced transfusionist coordinated the assignment of tasks and reporting. External reviewers of the guideline included a patient representative.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transfus Apher Sci Journal subject: HEMATOLOGIA Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transfus Apher Sci Journal subject: HEMATOLOGIA Year: 2024 Type: Article